Medical insurance price of osimertinib

Osimertinib, trade name Tagrisso, is a third-generation EGFR tyrosine kinase inhibitor (TKI) mainly used for Treatment of patients with EGFR mutation-positive non-small cell lung cancer (NSCLC), especially those who are resistant to first- and second-generation EGFR inhibitors (such as gefitinib and erlotinib). It blocks the growth signals of tumor cells by selectively inhibiting the mutant type of EGFR receptor, thereby inhibiting the growth and spread of tumors.

Osimertinib is particularly suitable for patients with T790M mutation-positive non-small cell lung cancer. The T790M mutation is the most common resistance mutation in the EGFR gene, making patients resistant to conventional EGFR inhibitors. Compared with previous generations of EGFR inhibitors, osimertinib is more resistant to the T790M mutation and therefore can effectively restore the therapeutic effect on tumors. In addition, the side effects of osimertinib are mild. Common adverse reactions include rash, diarrhea, fatigue, etc., and most of them are mild to moderate.

In China, osimertinib has been approved and marketed domestically. Since its launch, osimertinib has been widely used in the treatment of patients with EGFR mutation-positive advanced non-small cell lung cancer. The oral dose of osimertinib is 80 mg per time. It is usually taken once a day. Patients do not need to pay special attention to whether it is taken with food. The treatment is easy to use.

Osimertinib is currently included in China’s medical insurance. For eligible patients, medical insurance can provide a certain level of reimbursement to help reduce the patient's financial burden. According to the medical insurance policy, the price of osimertinib is approximately 3,000yuan per box, and each box contains 28 tablets. The specific medical insurance reimbursement ratio and scope of application may vary depending on the region and hospital. Therefore, it is recommended that patients consult the local hospital pharmacy or medical insurance agency for detailed medical insurance reimbursement information before purchasing the drug.

In general, osimertinib, as an innovative drug for the treatment of EGFR mutation-positive non-small cell lung cancer, has become an important treatment option for this type of patients due to its significant efficacy and relatively low side effects. With the promotion of medical insurance coverage, the burden on patients is expected to be further reduced.

xa0